MUC5B启动子变异rs35705950与类风湿关节炎相关间质性肺病的生存和进展
本研究为国际多中心回顾性观察研究,纳入261例类风湿关节炎相关间质性肺病(RA-ILD)患者,分析MUC5B rs35705950变异与无肺移植生存及肺功能进展的关系。结果显示该变异未影响无肺移植生存(HR=1.26,95%CI 0.61-2.62,P=0.53),也未影响2年肺功能下降(OR=0.95,95%CI 0.44-2.05,P=0.89)。
要点
- MUC5B rs35705950变异未影响RA-ILD患者无肺移植生存。
- 该变异未影响RA-ILD患者2年肺功能下降。
- 结果不受HRCT模式影响。
核心结论
- MUC5B rs35705950启动子变异未影响RA-ILD患者的无肺移植生存或肺功能下降。
研究设计与样本
- 国际回顾性观察研究,261例RA-ILD患者进行MUC5B rs35705950基因分型并收集连续肺功能检查,随访长达10年,采用混合回归模型、比例风险模型和联合比例风险模型分析。
主要发现
- 10年死亡率为32%(95%CI 19-42)。
- T风险等位基因携带者无肺移植生存的HR=1.26(95%CI 0.61-2.62,P=0.53)。
- 2年肺功能下降的OR=0.95(95%CI 0.44-2.05,P=0.89),不受HRCT模式影响。
关键数值与推荐
- RA-ILD显著进展定义为基线后2年内用力肺活量绝对或相对下降至少10%。
临床怎么用
- MUC5B rs35705950变异不宜用于预测RA-ILD患者的生存或肺功能进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The major risk factor for idiopathic pulmonary fibrosis (IPF), MUC5B rs35705950, was found to be associated with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Whilst the MUC5B rs35705950 T risk allele has been associated with better survival in IPF, its impact on RA-ILD prognosis remains to be determined. Our objective was to explore the influence of MUC5B rs35705950 on survival and progression in RA-ILD. METHODS: Through an international retrospective observational study, patients with RA-ILD were genotyped for the MUC5B rs35705950 variant and consecutive pulmonary function tests (PFTs) findings were collected. Longitudinal data up to a 10-year follow-up were considered and analyzed using mixed regression models. Proportional hazards and joint proportional hazards models were used to analyze the association of baseline and longitudinal variables with lung transplant-free survival. Significant progression of RA-ILD was defined as at least an absolute or relative 10% decline of forced vital capacity at 2 years from baseline. RESULTS: Out of 321 registered patients, 261 were included in the study: 139 women (53.3%), median age at RA-ILD diagnosis 65 years (interquartile range [IQR] 57 to 71), 151 ever smokers (59.2%). Median follow-up was 3.5 years (IQR 1.3 to 6.6). Mortality rate was 32% (95%CI 19 to 42) at 10 years. The MUC5B rs35705950 variant did not impact lung transplant-free survival (HR for the T risk allele carriers=1.26; 95%CI 0.61 to 2.62; P=0.53). Decline in pulmonary function at 2 years was not influenced by MUC5B rs35705950 (OR=0.95; 95%CI 0.44 to 2.05; P=0.89), irrespective of the HRCT pattern. CONCLUSION: In this study, the MUC5B rs35705950 promoter variant did not influence transplant- free survival or decline in pulmonary function in patients with RA-ILD.
引用
- Juge PA, Solomon JJ, van Moorsel CHM, et al. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum. 2021. PMID: 34411838. doi:10.1016/j.semarthrit.2021.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。